 | Related Articles |
Daratumumab, Elotuzumab, and the Development of Therapeutic Monoclonal Antibodies in Multiple Myeloma.
Clin Pharmacol Ther. 2017 Jan;101(1):81-88
Authors: Laubach JP, Paba Prada CE, Richardson PG, Longo DL
Abstract
There has been substantial progress in clinical outcomes for patients with multiple myeloma (MM). This encouraging trend derives in large part from the increasing number of effective therapeutic options and the ability because of this to achieve higher quality responses to treatment. The approval of both daratumumab and of elotuzumab in combination with lenalidomide and dexamethasone, in late 2015, was a notable achievement in the field, as daratumumab and elotuzumab represent the first monoclonal antibodies available for use in MM. Given their unique mechanisms of action and favorable side effect profiles, daratumumab and elotuzumab have considerable potential as therapeutic partners with agents in other drug classes and in different clinical settings ranging from newly diagnosed to relapsed disease. This review discusses the development of daratumumab and elotuzumab as well as other monoclonal antibodies currently being evaluated for use in MM.
PMID: 27806428 [PubMed - indexed for MEDLINE]
from #MedicinebyAlexandrosSfakianakis via xlomafota13 on Inoreader http://ift.tt/2sgCTE0
via IFTTT
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου